# Oseltamivir Phosphate

## Oseltamivir (政府提供) 6mg/mL 60mL oral suspension

| TAH Drug Code      | [LOSTA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=LOSTA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of influenza in adults and children (including full-term newborns). Prevention of influenza in adults and children aged 1 and above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Treatment of influenza: must begin treatment within the first or second day of experiencing influenza symptoms. - Adults and adolescents (>=13years): 75mg PO BID for 5 days. - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO BID for 5 days. >15-23kg: 45mg (7.5mL) PO BID for 5 days. >23-40kg: 60mg (10mL) PO BID for 5 days. >40kg: 75mg (12.5mL) PO BID for 5 days. - Children under 1 year: 3mg/kg PO BID for 5 days (not for infants with a gestational age of <36 weeks). Prophylaxis of influenza: must begin prophylaxis within 2 days of exposure to the source. - Adults and adolescents: 75mg PO QD for 10 or more days (safety and efficacy confirmed for 6 weeks). - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO QD for 10 days. >15-23kg: 45mg (7.5mL) PO QD for 10 days. >23-40kg: 60mg (10mL) PO QD for 10 days. > 40kg: 75mg (12.5mL) PO QD for 10 days. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Known allergies to oseltamivir phosphate or any of its components.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common: Nausea (8-10%), Vomiting (Adult and adolescent, 2-8%; pediatric, 8-16%), Headache (Influenza treatment, 2%; influenza prophylaxis, 17%) Serious: Cardiac dysrhythmia, Erythema multiforme (Rare), Facial swelling, Stevens-Johnson syndrome (Rare), Toxic epidermal necrolysis (Rare), Gastrointestinal hemorrhage, Hemorrhagic colitis, Hepatitis, Anaphylaxis (Rare), Seizure, Abnormal behavior, Delirium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

## Oseltamivir Phosphate 6mg/mL, 60mL oral suspension

| TAH Drug Code      | [LOSTAS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=LOSTAS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of influenza in adults and children (including full-term newborns). Prevention of influenza in adults and children aged 1 and above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Treatment of influenza: must begin treatment within the first or second day of experiencing influenza symptoms. - Adults and adolescents (>=13years): 75mg PO BID for 5 days. - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO BID for 5 days. >15-23kg: 45mg (7.5mL) PO BID for 5 days. >23-40kg: 60mg (10mL) PO BID for 5 days. >40kg: 75mg (12.5mL) PO BID for 5 days. - Children under 1 year: 3mg/kg PO BID for 5 days (not for infants with a gestational age of <36 weeks). Prophylaxis of influenza: must begin prophylaxis within 2 days of exposure to the source. - Adults and adolescents: 75mg PO QD for 10 or more days (safety and efficacy confirmed for 6 weeks). - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO QD for 10 days. >15-23kg: 45mg (7.5mL) PO QD for 10 days. >23-40kg: 60mg (10mL) PO QD for 10 days. > 40kg: 75mg (12.5mL) PO QD for 10 days. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Known allergies to oseltamivir phosphate or any of its components.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common: Nausea (8-10%), Vomiting (Adult and adolescent, 2-8%; pediatric, 8-16%), Headache (Influenza treatment, 2%; influenza prophylaxis, 17%) Serious: Cardiac dysrhythmia, Erythema multiforme (Rare), Facial swelling, Stevens-Johnson syndrome (Rare), Toxic epidermal necrolysis (Rare), Gastrointestinal hemorrhage, Hemorrhagic colitis, Hepatitis, Anaphylaxis (Rare), Seizure, Abnormal behavior, Delirium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

